Previously affiliated with the Lead Discovery Informatics (LDI) group of Novartis in Cambridge/MA, I am now developing and applying cheminformatics techniques in the drug discovery field in my group with the University of Cambridge. Our expertise ranges from the analysis of chemical screening data over the mode-of-action analysis of phenotypes (such as from high-content screening) to the prediction of adverse drug reactions. In case you are generating large amounts of chemical or biological data related to cancer drug discovery you are very welcome to contact me to see in which way I could contribute to your project.